Identification of patients with smouldering multiple myeloma at
ultra-high risk of progression using serum parameters: the
Czech Myeloma Group model

J 2020

Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model

HÁJEK, Roman; Viera SANDECKÁ; Ivan ŠPIČKA; Marc RAAB; Hartmut GOLDSCHMIDT et al.

Základní údaje

Originální název

Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model

Autoři

Vydání

British journal of haematology, Hoboken, Wiley-Blackwell, 2020, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.998

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116111

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

multiple myeloma; prognostic marker; risk factors; overall survival; progression-free survival

Štítky

14110518, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 8. 2020 13:15, Mgr. Tereza Miškechová

Anotace

V originále

Smouldering multiple myeloma (SMM) presents without MM defining symptoms. We aimed to identify patients with SMM with an 80% risk of progression within 2 years using only serum parameters. In total, 527 patients with SMM were included and divided into a training group (287 patients from the Czech Myeloma Group [CMG]) and an independent validation group (240 patients from Heidelberg). The median follow-up was 2 center dot 4 and 2 center dot 5 years, respectively. Progression to MM occurred in 51 center dot 9% of the CMG and 38 center dot 8% of the Heidelberg patients, respectively. The median risk of progression was 11 center dot 0% (CMG) and 9 center dot 7% (Heidelberg) per year, during the 5 years after diagnosis. A serum involved/uninvolved free light-chain ratio of >30, immunoparesis, and serum monoclonal (M) protein of >= 2 center dot 3 g/dl emerged as powerful predictors of 2-year progression rate with a hazard ratio (HR) of 2 center dot 49 (95% confidence interval [CI] 1 center dot 49-4 center dot 17), HR of 2 center dot 01 (95% CI 1 center dot 36-2 center dot 96) and HR of 2 center dot 00 (95% CI 1 center dot 44-2 center dot 79) (P < 0 center dot 001) in univariate Cox regression analysis, respectively. Based on this, the CMG model identified patients with SMM with a 2-year risk of progression of 78 center dot 7% (95% CI 53 center dot 1-95 center dot 7; HR 6 center dot 8;P < 0 center dot 001, CMG) and 81 center dot 3% (95% CI 47 center dot 1-98 center dot 8; HR 38 center dot 63;P < 0 center dot 001, Heidelberg). Serum parameters in the CMG model allow identification of patients with SMM with an 80% risk of progression to symptomatic MM within 2 years.

Citovat

HÁJEK, Roman; Viera SANDECKÁ; Ivan ŠPIČKA; Marc RAAB; Hartmut GOLDSCHMIDT; Susanne BECK; Jiří MINAŘÍK; Petr PAVLÍČEK; Jakub RADOCHA; Adriana HEINDORFER; Tomáš JELÍNEK; Lukáš STEJSKAL; Lucie BROŽOVÁ; Sabina ŠEVČÍKOVÁ; Jan STRAUB; Tomáš PIKA; Luděk POUR; Vladimír MAISNAR; Anja SECKINGER a Dirk HOSE. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. British journal of haematology. Hoboken: Wiley-Blackwell, 2020, roč. 190, č. 2, s. 189-197. ISSN 0007-1048. Dostupné z: https://doi.org/10.1111/bjh.16572.

@article{1672837,
   author = {Hájek, Roman and Sandecká, Viera and Špička, Ivan and Raab, Marc and Goldschmidt, Hartmut and Beck, Susanne and Minařík, Jiří and Pavlíček, Petr and Radocha, Jakub and Heindorfer, Adriana and Jelínek, Tomáš and Stejskal, Lukáš and Brožová, Lucie and Ševčíková, Sabina and Straub, Jan and Pika, Tomáš and Pour, Luděk and Maisnar, Vladimír and Seckinger, Anja and Hose, Dirk},
   article_location = {Hoboken},
   article_number = {2},
   doi = {https://doi.org/10.1111/bjh.16572},
   keywords = {multiple myeloma; prognostic marker; risk factors; overall survival; progression-free survival},
   language = {eng},
   issn = {0007-1048},
   journal = {British journal of haematology},
   title = {Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model},
   url = {https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16572},
   volume = {190},
   year = {2020}
}

TY  - JOUR
ID  - 1672837
AU  - Hájek, Roman - Sandecká, Viera - Špička, Ivan - Raab, Marc - Goldschmidt, Hartmut - Beck, Susanne - Minařík, Jiří - Pavlíček, Petr - Radocha, Jakub - Heindorfer, Adriana - Jelínek, Tomáš - Stejskal, Lukáš - Brožová, Lucie - Ševčíková, Sabina - Straub, Jan - Pika, Tomáš - Pour, Luděk - Maisnar, Vladimír - Seckinger, Anja - Hose, Dirk
PY  - 2020
TI  - Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model
JF  - British journal of haematology
VL  - 190
IS  - 2
SP  - 189-197
EP  - 189-197
PB  - Wiley-Blackwell
SN  - 00071048
KW  - multiple myeloma
KW  - prognostic marker
KW  - risk factors
KW  - overall survival
KW  - progression-free survival
UR  - https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16572
L2  - https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16572
N2  - Smouldering multiple myeloma (SMM) presents without MM defining symptoms. We aimed to identify patients with SMM with an 80% risk of progression within 2 years using only serum parameters. In total, 527 patients with SMM were included and divided into a training group (287 patients from the Czech Myeloma Group [CMG]) and an independent validation group (240 patients from Heidelberg). The median follow-up was 2 center dot 4 and 2 center dot 5 years, respectively. Progression to MM occurred in 51 center dot 9% of the CMG and 38 center dot 8% of the Heidelberg patients, respectively. The median risk of progression was 11 center dot 0% (CMG) and 9 center dot 7% (Heidelberg) per year, during the 5 years after diagnosis. A serum involved/uninvolved free light-chain ratio of >30, immunoparesis, and serum monoclonal (M) protein of >= 2 center dot 3 g/dl emerged as powerful predictors of 2-year progression rate with a hazard ratio (HR) of 2 center dot 49 (95% confidence interval [CI] 1 center dot 49-4 center dot 17), HR of 2 center dot 01 (95% CI 1 center dot 36-2 center dot 96) and HR of 2 center dot 00 (95% CI 1 center dot 44-2 center dot 79) (P < 0 center dot 001) in univariate Cox regression analysis, respectively. Based on this, the CMG model identified patients with SMM with a 2-year risk of progression of 78 center dot 7% (95% CI 53 center dot 1-95 center dot 7; HR 6 center dot 8;P < 0 center dot 001, CMG) and 81 center dot 3% (95% CI 47 center dot 1-98 center dot 8; HR 38 center dot 63;P < 0 center dot 001, Heidelberg). Serum parameters in the CMG model allow identification of patients with SMM with an 80% risk of progression to symptomatic MM within 2 years.
ER  -

HÁJEK, Roman; Viera SANDECKÁ; Ivan ŠPIČKA; Marc RAAB; Hartmut GOLDSCHMIDT; Susanne BECK; Jiří MINAŘÍK; Petr PAVLÍČEK; Jakub RADOCHA; Adriana HEINDORFER; Tomáš JELÍNEK; Lukáš STEJSKAL; Lucie BROŽOVÁ; Sabina ŠEVČÍKOVÁ; Jan STRAUB; Tomáš PIKA; Luděk POUR; Vladimír MAISNAR; Anja SECKINGER a Dirk HOSE. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. \textit{British journal of haematology}. Hoboken: Wiley-Blackwell, 2020, roč.~190, č.~2, s.~189-197. ISSN~0007-1048. Dostupné z: https://doi.org/10.1111/bjh.16572.

Přehled o publikaci